Summary
Respiratory disease is common in children and strongly associated with lifestyle and environmental exposures. Thus, it is important to study the epidemiology locally. LuftiBus in the school (LUIS) was set up to assess the respiratory health of schoolchildren in the canton of Zurich, Switzerland.
LUIS is a cross-sectional population-based study that was carried out 2013 to 2016. Children aged 6-17 years living in the canton of Zurich were eligible to participate. All schools in the canton were approached and the school head decided whether the school would participate and with which classes. Consenting parents answered a standardized questionnaire at home and assenting children completed a shorter questionnaire by interview at school. Trained technicians measured children’s lung function including spirometry, double tracer gas single-breath washout (DTG-SBW) and fractional exhaled nitric oxide (FeNO). Address histories of participants were geocoded to be linked with area-based socioeconomic measures and environmental exposures like spatiotemporal air pollution estimates for specific time periods and locations. A subgroup was seen again 12 months later using the same procedures to collect longitudinal data.
The study included 3870 children at baseline and 655 at the one-year follow-up. Median age was 12.7 years; 281 (8%) had wheezed in the past year. At baseline we collected 3457 (89%) parental and 3546 (92%) children’s questionnaires, and 3393 (88%) FeNO, 3446 (89%) spirometry, and 1795 (46%) DTG-SBW measurements.
LUIS is a rich resource of health-related data, with information on lung function, environmental exposures and respiratory health on Swiss schoolchildren.
Take home message LuftiBus in the school (LUIS) is a population-based study with detailed lung function data and rich information on respiratory health in Swiss schoolchildren.
Competing Interest Statement
Dr. Moeller reports grants from Lunge Zuerich, personal fees from Vertex Inc, during the conduct of the study. Dr. Singer reports personal fees from Novartis, personal fees from Vertex, outside the submitted work. Dr. Usemann reports personal fees from Vertex, during the conduct of the study. Dr. Latzin reports personal fees from Vertex, personal fees from Novartis, personal fees from Roche, personal fees from Polyphor, personal fees from Vifor, personal fees from Gilead, personal fees from Schwabe, personal fees from Zambon, personal fees from Santhera, grants from Vertex, outside the submitted work.
Funding Statement
Lunge Zuerich, Switzerland, funded the study set-up, development and data collection with a grant to Alexander Moeller. Lunge Zuerich, Switzerland, and University Children's Hospital Zurich and Children's Research Center, University of Zurich, Switzerland, funds LUIS data management, data analysis and publications. Analysis has been supported by a grant of the Swiss National Science Foundation (320030_173044) to Claudia Kuehni and an Ambizione grant of the Swiss National Science Foundation to Myrofora Goutaki (P200P3_185923). Further analyses are funded by a grant of Lungenliga Bern, Switzerland, to Florian Singer, a grant of Lungenliga Schweiz to Jakob Usemann and a grant of Stiftung Batzebaer to Johanna Kurz.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the canton of Zurich approved the study (KEK-ZH-Nr: 2014-0491).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Study collaborators and other researchers can obtain datasets for analysis if a detailed concept sheet is presented for the planned analyses and approved by the principal investigators (AM, PL and CK).
